当前位置: X-MOL 学术Postgrad. Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Gastroparesis with Cannabis Use: A Retrospective Study from the Nationwide Inpatient Sample
Postgraduate Medicine ( IF 2.6 ) Pub Date : 2021-06-15 , DOI: 10.1080/00325481.2021.1940219
Dushyant Singh Dahiya 1 , Asim Kichloo 1, 2 , Hafeez Shaka 3 , Jagmeet Singh 4 , Ehizogie Edigin 3 , Dhanshree Solanki 5 , Precious Obehi Eseaton 6 , Farah Wani 7
Affiliation  

ABSTRACT

Background: With increasing utilization of cannabis in the United States (US), clinicians may encounter more cases of Gastroparesis (GP) in coming years.

Objective: The primary outcome was inpatient mortality for GP with cannabis use. Secondary outcomes included system-based complications and the burden of the disease on the US healthcare system.

Methods: From the Nationwide Inpatient Sample (NIS), we identified adult hospitalizations with a primary discharge diagnosis of GP for 2016 and 2017. Individuals ≤18 years of age were excluded. The study population was subdivided based on a secondary diagnosis of cannabis use. The outcomes included biodemographic characteristics, mortality, complications, and burden of disease on the US healthcare system.

Results: For 2016 and 2017, we identified 99,695 hospitalizations with GP. Of these hospitalizations, 8,870 had a secondary diagnosis of cannabis use while 90,825 served as controls. The prevalence of GP with cannabis use was 8.9%. For GP with cannabis use, the patients were younger (38.5 vs 48.1 years, p < 0.001) with a Black predominance (Table 1) and lower proportion of females (52.3 vs 68.3%, p < 0.001) compared to the non-cannabis use cohort. Additionally, the cannabis use cohort had higher percentage of patients with co-morbidities like hypertension, diabetes mellitus and a history of smoking. The inpatient mortality for GP with cannabis use was noted to be 0.27%. Furthermore, we noted shorter mean length of stay (LOS) (3.4 vs 4.4 days, aMD: −0.7, 95%CI: −0.9 – [−0.5], p < 0.001), lower mean total hospital charge (THC) ($30,400 vs $38,100, aMD: −5100, 95%CI: −6900 – [−3200], p < 0.001), and lower rates of sepsis (0.11 vs 0.60%, aOR: 0.22, 95% CI: 0.05–0.91, p = 0.036) for GP hospitalizations with cannabis use compared to the non-cannabis use cohort.

Conclusion: Inpatient mortality for GP hospitalizations with cannabis use was 0.27%. Additionally, these patients had shorter LOS, lower THC, and lower sepsis rates.



中文翻译:

使用大麻引起的胃轻瘫:一项来自全国住院患者样本的回顾性研究

摘要

背景:随着美国(US)大麻使用量的增加,未来几年临床医生可能会遇到更多的胃轻瘫(GP)病例。

目的:主要结果是使用大麻的 GP 住院死亡率。次要结果包括基于系统的并发症和疾病对美国医疗保健系统的负担。

方法:从全国住院患者样本 (NIS) 中,我们确定了 2016 年和 2017 年首次出院诊断为 GP 的成人住院患者。排除了 18 岁以下的个体。根据对大麻使用的二次诊断,对研究人群进行了细分。结果包括美国医疗保健系统的生物人口学特征、死亡率、并发症和疾病负担。

结果:在 2016 年和 2017 年,我们确定了 99,695 例全科医生住院治疗。在这些住院治疗中,8,870 人二次诊断为使用大麻,而 90,825 人作为对照。使用大麻的 GP 患病率为 8.9%。对于使用大麻的 GP,与不使用大麻的患者相比,患者更年轻(38.5 岁与 48.1 岁,p < 0.001),黑人占优势(表 1),女性比例较低(52.3 与 68.3%,p < 0.001)队列。此外,使用大麻的人群中患有高血压、糖尿病和吸烟史等并发症的患者比例更高。使用大麻的 GP 住院死亡率为 0.27%。此外,我们注意到平均住院时间 (LOS) 较短(3.4 天对 4.4 天,aMD:-0.7,95%CI:-0.9 – [-0.5],p < 0.001),平均住院总费用 (THC) 较低($30,400与 38,100 美元相比,

结论:因使用大麻而住院的 GP 住院死亡率为 0.27%。此外,这些患者的 LOS 更短,THC 更低,败血症率更低。

更新日期:2021-06-15
down
wechat
bug